Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

1. The Role of Glucose Transporters in Oral Squamous Cell Carcinoma.Biomolecules · 2021
   Pooled it
2. The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities.Neoplasia (New York, N.Y.) · 2024
   Review
3. BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies.Frontiers in oncology · 2024
   Review
4. Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma.International journal of molecular sciences · 2023
   Review
5. Long noncoding RNA DIO3OS induces glycolytic-dominant metabolic reprogramming to promote aromatase inhibitor resistance in breast cancer.Nature communications · 2022
   Article
6. Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network.Biomolecules · 2022
   Review
7. Glycolysis-induced drug resistance in tumors-A response to danger signals?Neoplasia (New York, N.Y.) · 2021
   Review
8. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance.Cell death & disease · 2020
   Review
9. Genome instability in multiple myeloma.Leukemia · 2020
   Review
10. How the evolution of multicellularity set the stage for cancer.British journal of cancer · 2018
    Review
11. Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
12. The hypoxia signalling pathway in haematological malignancies.Oncotarget · 2017
    Review
13. Mcl-1 expression and JNK activation induces a threshold for apoptosis in Bcl-xL-overexpressing hematopoietic cells.Oncotarget · 2017
    Article
14. Low carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics.Oncotarget · 2016
    Article
15. SIRT2 activates G6PD to enhance NADPH production and promote leukaemia cell proliferation.Scientific reports · 2016
    Article
16. Targeting cell death signalling in cancer: minimising 'Collateral damage'.British journal of cancer · 2016
    Review
17. Non-thermal plasma with 2-deoxy-D-glucose synergistically induces cell death by targeting glycolysis in blood cancer cells.Scientific reports · 2015
    Article
18. Targeting aerobic glycolysis and HIF-1alpha expression enhance imiquimod-induced apoptosis in cancer cells.Oncotarget · 2014
    Article
19. GAPDH binds to active Akt, leading to Bcl-xL increase and escape from caspase-independent cell death.Cell death and differentiation · 2013
    Article
20. Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance.Cancer research · 2013
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors at 4 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as